Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDH305 · 1 trial · 1 indication
To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)
| Arm | Type | Description |
|---|---|---|
| IDH305 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IDH305 | DRUG | - |
Inclusion Criteria: * Documented IDH1R132-mutant tumors * ECOG performance status ≤ 2 Exclusion Criteria: * Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients) * Medical conditions that would prevent the patient's participation ...
IDH305 is an investigational small molecule being developed for the treatment of advanced malignancies that harbor IDH1R132 mutations. It is currently in Phase 1 clinical development for this oncology indication.
IDH305 targets the IDH1R132 mutation, which is a specific genetic alteration found in certain advanced malignancies. By targeting this mutation, the drug is designed to address cancers that carry this particular genetic change.
IDH305 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development.
IDH305 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is actively enrolling patients, though recruitment is currently not active.
IDH305 is being studied in a single Phase 1 clinical trial with the identifier NCT02381886. This trial is investigating the drug in patients with advanced malignancies that harbor IDH1R132 mutations, with an enrollment of 166 participants across multiple countries.
IDH305 is the drug name used in clinical development. No alternative names have been reported for this investigational agent. It is being studied under the trial identifier NCT02381886 for advanced malignancies with IDH1R132 mutations.